

## PT2567

Peloton is developing a distinct HIF-2 $\alpha$  antagonist, PT2567, as a novel treatment for pulmonary arterial hypertension (PAH) that could prevent and reverse the remodeling of blood vessels in the lung. Peloton also plans to evaluate PT2567 in inflammatory bowel disease and nonalcoholic steatohepatitis (NASH), two prevalent, debilitating diseases in which the rationale for HIF-2 $\alpha$  inhibition is strong.